Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer.

ABSTRACT:

Aim

Pemetrexed, a new generation antifolate drug, has been approved for the treatment of locally advanced or metastatic breast cancer. However, factors affecting its efficacy and resistance have not been fully elucidated yet. ATP-binding cassette (ABC) transporters are predictors of prognosis as well as of adverse effects of several xenobiotics. This study was designed to explore whether ABC transporters affect pemetrexed resistance and can contribute to the optimization of breast cancer treatment regimen.

Methods

First, we measured the expression levels of ABC transporter family members in cell lines. Subsequently, we assessed the potential role of ABC transporters in conferring resistance to pemetrexed in primary breast cancer cells isolated from 34 breast cancer patients

SUBMITTER: Chen J 

PROVIDER: S-EPMC7908708 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature